Article Text

Download PDFPDF
PATRICIA randomised controlled trial
High efficacy of HPV 16/18 AS04-adjuvanted vaccine shown against CIN2+ associated with HPV-16/18 and non-vaccine oncogenic HPV types
  1. Lisa Rambout
  1. Lisa Rambout
    Division of Gynaecologic Oncology, Department of Pharmacy, The Ottawa Hospital, General Campus, 501 Smyth Road, Ottawa, Ontario, Canada K1H 8L6; lrambout{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlCrossRefPubMedWeb of Science

At least three out of every four women will acquire human papillomavirus (HPV), the world’s most common sexually transmitted viral infection, at some time in their lives.1 The full burden of HPV comprises a broad spectrum of health impacts from screening to the development of invasive cervical cancer and death. Worldwide, more than half a million women are diagnosed with cervical cancer each year, and more than a quarter of a million women die from the disease, typically in the prime of their lives.2 Accordingly, the final results of the PATRICIA trial address an important public health problem. They provide more robust efficacy data for clinically relevant pre-cancer disease outcomes, add to our knowledge regarding the duration of vaccine efficacy, …

View Full Text


  • Competing interests None.